CINECA IRIS Institutional Research Information System

DI NICOLANTONIO, Federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.755
EU - Europa 11.616
AS - Asia 9.124
SA - Sud America 412
OC - Oceania 260
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 32
Totale 37.314
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.121
CN - Cina 5.566
IT - Italia 3.646
GB - Regno Unito 1.151
DE - Germania 1.068
JP - Giappone 952
FR - Francia 923
IE - Irlanda 627
RU - Federazione Russa 554
SE - Svezia 510
ES - Italia 509
KR - Corea 482
CA - Canada 474
IN - India 415
NL - Olanda 397
PL - Polonia 389
HK - Hong Kong 311
TW - Taiwan 290
FI - Finlandia 278
UA - Ucraina 252
BE - Belgio 219
TR - Turchia 216
AU - Australia 213
VN - Vietnam 198
CH - Svizzera 186
GR - Grecia 153
SG - Singapore 151
DK - Danimarca 146
BR - Brasile 138
AT - Austria 136
MX - Messico 132
IL - Israele 89
RO - Romania 88
PT - Portogallo 75
TH - Thailandia 70
NO - Norvegia 66
HU - Ungheria 65
CZ - Repubblica Ceca 63
PE - Perù 62
AR - Argentina 59
CO - Colombia 58
IR - Iran 50
CL - Cile 47
NZ - Nuova Zelanda 46
SA - Arabia Saudita 40
ID - Indonesia 37
MY - Malesia 36
AM - Armenia 28
SN - Senegal 28
EC - Ecuador 26
JO - Giordania 26
PH - Filippine 24
EG - Egitto 17
EU - Europa 17
HR - Croazia 16
LB - Libano 16
MO - Macao, regione amministrativa speciale della Cina 16
NG - Nigeria 16
PK - Pakistan 16
KZ - Kazakistan 15
SK - Slovacchia (Repubblica Slovacca) 14
TN - Tunisia 14
SI - Slovenia 13
PS - Palestinian Territory 12
AE - Emirati Arabi Uniti 11
RS - Serbia 11
UZ - Uzbekistan 11
ZA - Sudafrica 11
BA - Bosnia-Erzegovina 10
GY - Guiana 10
AP - ???statistics.table.value.countryCode.AP??? 9
BY - Bielorussia 8
CY - Cipro 8
DZ - Algeria 8
PR - Porto Rico 8
QA - Qatar 8
BG - Bulgaria 7
BN - Brunei Darussalam 7
LV - Lettonia 7
GH - Ghana 6
MA - Marocco 6
NI - Nicaragua 6
UY - Uruguay 6
EE - Estonia 5
ET - Etiopia 5
IS - Islanda 5
KH - Cambogia 5
LT - Lituania 5
LU - Lussemburgo 5
PA - Panama 5
HN - Honduras 4
IQ - Iraq 4
VE - Venezuela 4
A1 - Anonimo 3
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
LK - Sri Lanka 3
MK - Macedonia 3
MT - Malta 3
TZ - Tanzania 3
Totale 37.294
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.552
Beijing 1.234
Chandler 940
Fairfield 818
Houston 791
Shanghai 692
Redwood City 624
Dublin 581
Torino 539
Ashburn 459
Woodbridge 453
Seattle 434
Wilmington 433
Guangzhou 428
Hangzhou 404
Cambridge 381
Dearborn 376
Milan 272
Tokyo 246
Villeurbanne 236
Nanjing 224
Pisa 216
New York 206
Turin 195
Warsaw 191
Nyköping 179
Jacksonville 169
Princeton 168
Boston 163
Medford 155
Wuhan 151
Taipei 147
Rome 144
Chengdu 116
London 113
Barcelona 108
Paris 105
Dong Ket 103
Fremont 103
Seoul 100
San Diego 99
Toronto 97
Buffalo 94
Shenzhen 93
Shenyang 90
Brussels 84
Vienna 83
Amsterdam 78
Ottawa 78
Berlin 75
Changsha 75
Duncan 75
Central District 72
Los Angeles 72
Central 71
Zhengzhou 68
Jinan 67
Tianjin 67
Xian 64
Chicago 63
Chongqing 62
Munich 60
Madrid 57
Phoenix 56
Singapore 56
Utrecht 52
Istanbul 51
Helsinki 50
Kunming 50
San Francisco 49
Carrara 48
Washington 48
Lima 47
Falls Church 46
Genoa 46
Norwalk 46
Daejeon 45
Rochester 44
Boardman 43
Dundee 43
Manchester 43
Pune 43
Harbin 41
Nanchang 41
Zurich 41
Bologna 40
Philadelphia 40
Fuzhou 39
Southend 39
Stuttgart 39
Hefei 38
Hyderabad 38
Silver Spring 38
Sydney 38
Heidelberg 37
Ankara 36
Brooklyn 36
Montréal 35
Oslo 35
Birmingham 34
Totale 19.284
Salva come PNG Salva come JPEG
Nome #
High-dose Vitamin C enhances cancer immunotherapy 3.907
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 3.695
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2.016
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.646
Adaptive mutability of colorectal cancers in response to targeted therapies 1.573
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 1.237
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.095
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.042
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model 802
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 686
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer 637
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 571
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 547
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 535
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 534
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer 528
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 522
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 480
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 451
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 439
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. 436
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 411
Costruzione di linee cellulari isogeniche per mutazioni associate al cancro e loro applicazione per approcci di farmacogenomica 401
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 357
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients 346
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer 307
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer 306
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS 289
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 283
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 272
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 261
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 252
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. 238
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 238
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers 226
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. 225
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung 218
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs 213
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti– Epidermal Growth Factor Receptor Antibody Therapies 212
Exploiting DNA repair defects in colorectal cancer 208
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 207
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 203
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. 200
Liquid biopsy: monitoring cancer-genetics in the blood 190
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 188
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination 185
Acquired resistance to EGFR-targeted therapies in colorectal cancer. 184
Evolving neoantigen profiles in colorectal cancers with DNA repair defects 183
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies 179
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin 174
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 170
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 163
Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma 154
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 153
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia 153
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 150
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. 149
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 147
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 144
Kras mutations and resistance to anti-egfr treatment 138
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 138
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 135
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing? 130
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility 130
ISOGENIC HUMAN CELL LINES COMPRISING MUTATED CANCER ALLELES AND PROCESS USING THE CELL LINES 128
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 123
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours 123
Anti-EGFR Antibody Therapy Based on an Increased Copy Number of the EGFR Gene in Tumor Tissues 119
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies 114
Fibroblast Growth Factor Receptor (FGFR)3 sustains acquired resistance to trastuzumab in gastric cancer patients 112
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study 110
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. 108
EMERGENCE OF KRAS MUTATIONS AND ACQUIRED RESISTANCE TO ANTI EGFR THERAPY IN COLORECTAL CANCER 107
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 106
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 105
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 105
Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer 105
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 102
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. 100
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer 98
Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells 96
BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer 95
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells 94
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening 94
Cancer cell adaptation to chemotherapy 93
Climbing RAS, the Everest of Oncogenes. 93
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. 93
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses 91
Kinase mutations in cancer: chinks in the enemy's armour? 90
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer 90
The chemosensitivity profile of retinoblastoma 87
Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines 86
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma 86
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies 85
RAF Inhibitors 84
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer 84
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer 83
Transfection and DNA-Mediated Gene Transfer 77
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 76
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer 75
Totale 36.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.224
article - articoli 0
book - libri 0
conference - conferenze 3.150
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.430 0 0 0 0 0 0 0 0 0 374 662 394
2019/20205.032 342 267 327 553 411 670 438 366 507 466 388 297
2020/20216.101 302 300 463 537 539 507 611 393 566 581 429 873
2021/20227.343 814 822 767 942 470 399 521 464 530 366 680 568
2022/20236.607 484 435 407 512 443 875 510 483 1.146 348 528 436
2023/20244.538 531 508 480 474 543 531 393 506 183 389 0 0
Totale 38.206